A Phase IIIB Study to Compare the Efficacy and Safety of Concomitant Treatment in Patients With COPD

A 6-Week Double-Blind, Parallel-Group, Active-Controlled Trial to Compare the Efficacy and Safety of Concomitant Treatment of Formoterol Fumarate Inhalation Solution 20 Mcg Twice Daily and Tiotropium 18 Mcg Once Daily to Tiotropium 18 Mcg Once Daily Alone in the Treatment of Patients With Chronic Obstructive Pulmonary Disease

The purpose of this study is to evaluate the safety and efficacy of the concomitant treatment of formoterol fumarate with tiotropium bromide compared to treatment with tiotropium bromide alone.

Inclusion Criteria:

• Medical diagnosis of COPD
• Current or prior history of cigarette smoking

Exclusion Criteria:

• Medical diagnosis of asthma
• Significant condition or disease other than COPD